New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
04:55 EDTSI, SI, SI, THOR, THOR, THOR, STJ, STJ, STJ, ATRC, ATRC, ATRC, CADX, CADX, CADX, COV, COV, COV, CRY, CRY, CRY, EW, EW, EW, HTWR, HTWR, HTWR, ISRG, ISRG, ISRG, MDT, MDT, MDT, MYGN, MYGN, MYGN, RTIX, RTIX, RTIX, WTKWY, WTKWY, WTKWYAmerican Association for Thoracic Surgery to hold annual meeting
94th Annual Meeting of AATS is being held in Toronto on April 26-30.
News For SI;RTIX;MYGN;MDT;ISRG;HTWR;EW;CRY;COV;CADX;ATRC;STJ;THOR;WTKWY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 3, 2016
09:19 EDTEWOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
February 2, 2016
19:22 EDTMYGN, EWOn The Fly: After Hours Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 16.5%... Wabash National (WNC), up 9.7%... Oclaro (OCLR), up 6.8%... Myriad Genetics (MYGN), up 8%... Ultimate Software Group (ULTI), up 6.2%... Natural Health (NHTC), up 6.2%... Edwards Lifesciences (EW), up 6.2%... Viavi Solutions (VIAV), up 2.4%... Gilead Sciences (GILD), up just under 1%. DOWN AFTER EARNINGS: Match Group (MTCH), down 7.3%... Yahoo (YHOO), down 1.2%... Chipotle (CMG), down 7.1%. ALSO LOWER: Barnes & Noble (BKS), down 2.4% after General Growth (GGP) CEO Sandeep Mathrani announced that Amazon (AMZN) is going to open 300-400 brick-and-mortar bookstores.
16:26 EDTEWEdwards Lifesciences up 4.3% after reporting Q4 results, giving guidance
16:25 EDTEWEdwards Lifesciences raises FY16 adjusted EPS view to $2.57-$2.67
Consensus $2.40. Raises FY16 revenue guidance to $2.6B-$2.85B, consensus $2.69B.
16:24 EDTEWEdwards Lifesciences sees Q1 adjusted EPS 64c-70c, consensus 59c
Subscribe for More Information
16:22 EDTEWEdwards Lifesciences reports Q4 adjusted EPS 63c, consensus 62c
Reports Q4 revenue $671.1M, consensus $648.74M.
16:10 EDTMYGNMyriad Genetics sees FY16 EPS $1.63-$1.68, consensus $1.64
Sees FY16 revenue $750-$770M , consensus $759.25M.
16:09 EDTMYGNMyriad Genetics sees Q3 EPS 37c-39c, consensus 40c
Subscribe for More Information
16:07 EDTMYGNMyriad Genetics reports Q2 EPS 45c, consensus 41c
Subscribe for More Information
14:32 EDTMYGN, EWNotable companies reporting after market close
Subscribe for More Information
12:25 EDTEWEdwards Lifesciences technical notes ahead of earnings
Subscribe for More Information
February 1, 2016
10:02 EDTMDTMedtronic announced CE Mark, commercial launch for Resolute Onyx expansion
Medtronic announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next generation drug-eluting stent that is now available in 4.5mm and 5.0mm diameter sizes. The CE Mark also approved several new product indications including treatment of left main vessels and small vessels. Many coronary vessels are large in diameter of which a sub-set are left main, and now physicians can treat these large vessels with optimally sized stents that provide appropriate drug concentration. Resolute Onyx is the first DES available in these sizes among major manufacturers, offering the broadest size matrix to optimize the treatment of complex clinical scenarios. The Resolute Onyx DES is not commercially available in the United States.
08:05 EDTMDTMedtronic acquires Bellco
Medtronic announced it acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions. Bellco's portfolio bolsters Medtronic's legacy renal access business and will be a foundational component of the company's recently formed Renal Care Solutions business. The Bellco transaction is expected to meet Medtronic's long-term financial metrics for acquisitions. Medtronic expects the net impact from the transaction to be earnings neutral in FY16 and neutral to accretive to earnings thereafter.
January 29, 2016
16:25 EDTMDTMedtronic to present transcatheter pacing data to FDA
Subscribe for More Information
January 28, 2016
13:34 EDTHTWRHeartWare upgraded to Outperform from Market Perform at Wells Fargo
11:11 EDTSTJ, HTWRHeartWare rallies after scrapping Valtech acquisition
The shares of HeartWare (HTWR) are surging after the company announced that would terminate its acquisition of privately held Valtech. Two research firms reacted positively to the news, with Leerink Swann saying that the company made the right decision, given its current difficulties and Raymond James upgrading HeartWare following the news. HeartWare develops and manufactures miniaturized implantable heart pumps, while Valtech has developed a method of replacing mitral valves in human hearts without the need for open heart surgery. WHAT'S NEW: HeartWare decided to terminate its acquisition of Valtech, the companies announced this morning. Pursuant to the terms of the agreement, HeartWare will make a $30M loan to Valtech in the form of a convertible promissory note. ANALYST REACTION: HeartWare's decision to abandon its acquisition of Valtech was correct in light of the problems that the company is facing with its next generation MVAD pump, Leerink analyst Danielle Antalffy wrote in a note to investors today. Noting that two weeks ago HeartWare announced that it would investigate suction issues that the device has had, the analyst says that fixing the pump could require additional investment, while it's uncertain how long it will take to solve the device's problems. However, the analyst remained upbeat on Heartware's current LVAD products, and believes that it can compete with next generation systems. She kept a $60 price target and Outperform rating on the shares. Raymond James upgraded HeartWare to Outperform from Market Perform, saying that the termination of the Valtech deal removes an overhang on the shares, while the stock's underperformance since September has made its valuation more attractive. Moreover, the stock does not appear to be giving any value to the problematic MVAD pump and the company has a 37% share of a $760M market that has only two main competitors and high barriers to entry, the firm wrote. WHAT'S NOTABLE: In early October 2015, activist investor Engaged Capital urged HeartWare to terminate the Valtech deal. Today HeartWare announced that it would, in conjunction with Engaged Capital, "jointly select" an independent party who will join Heartware's board. ANOTHER TO WATCH: HeartWare's chief rival, Thoratec, was acquired last year by St. Jude Medical (STJ). PRICE ACTION: In late morning trading, HeartWare rose 10% to $37.95. St. Jude, which reported its fourth quarter results and gave fiscal year guidance this morning, is down 1.4% to $53.56.
09:50 EDTHTWRHeartWare upgraded to Outperform from Market Perform at Raymond James
Subscribe for More Information
09:38 EDTHTWRHeartWare likely to trade 'sharply higher' on deal termination, says Leerink
Subscribe for More Information
06:14 EDTHTWRHeartWare announces cooperation agreement with Engaged Capital
Subscribe for More Information
06:13 EDTHTWRHeartWare, Valtech Cardio announce termination of proposed acquisition
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use